- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Rational molecular design of two-photon activated temoporfin: a computational study for advanced photodynamic therapy. (Pubmed Central) - Jul 10, 2025
Simulations in a biological membrane model confirmed favorable interactions and localization of the candidate PDT agents within lipid bilayers, supporting their potential for enhanced clinical applications. This study demonstrates that rational molecular design can improve both the optical properties and the drug-delivery proficiency of temoporfin, paving the way for more effective deep-tissue PDT treatments.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Exploring the impact of photodynamic therapy conditioning on endometrial cancer cells (Poster and Exhibition Hall; Poster Board No EACR25-2370) - Jun 29, 2025 - Abstract #EACR2025EACR_788;
Nevertheless, temoporfin appears to potentiate the migration ability of HEC-1-A cells. FCT supports CIBB (doi:10.54499/UIDB/04539/2020; doi:10.54499/UIDP/04539/2020; doi:10.54499/LA/P/0058/2020); CQC (doi:10.54499/UIDB/00313/2020; doi:10.54499/UIDP/00313/2020; TEMA (doi:10.54499/UIDB/00481/2020), UIDP/00481/2020 (doi:10.54499/UIDP/00481/2020); Projects CarboNCT (doi:10.54499/2022.03596.PTDC) and Chem4LungCare (doi:10.54499/PTDC/QUI-QOR/0103/2021); PhD Scholarship from FCT and European Social Fund to BS (10.54499/2020.07672.BD).
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Significant Tumor Inhibition of Trimethyl-152-[L-aspartyl]pheophorbide a in Tumor Photodynamic Therapy (Pubmed Central) - May 21, 2025
It exhibited excellent phototoxicity higher than reference compound m-THPC when irradiated by 650?nm light in?vitro, and obvious photodynamic anti-tumor effect in?vivo...The observed high efficacy was rationalized by efficient introduction into the blood by facile transfer through membranes, which is supported by molecular dynamics simulation studies. This work provides a new candidate photosensitizer for anti-cancer treatment.
- |||||||||| ABV-1601 / ABVC BioPharma, ABV-1504 / ABVC BioPharma
Trial completion date, Trial primary completion date: A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients (clinicaltrials.gov) - Feb 11, 2025
P1/2, N=12, Not yet recruiting,
Push-out bond strength was highest in Group 2 (9.98 Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027
- |||||||||| Foscan (temoporfin) / ABVC BioPharma, velpatasvir (GS-5816) / Gilead, Visudyne (verteporfin) / Novartis
Journal: Drug repositioning identifies potential autophagy inhibitors for the LIR motif p62/SQSTM1 protein. (Pubmed Central) - Dec 13, 2024
Finally, we experimentally confirmed that Kanamycin can inhibit autophagy-associated acidic vesicular formation in breast cancer MCF-7 and MDA-MB 231 cells. These repositioned drugs may represent novel autophagy modulators in clinical management, warranting further investigation.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Efficient Delivering of a Photodynamic Therapy Drug into Cellular Membranes Rationalized by Molecular Dynamics. (Pubmed Central) - Nov 28, 2024
In this article, we rationalize the behavior of a temoporfin-based PDT drug, commercialized under the name of Foscan, complexed by two ?-cyclodextrin units, acting as drug carriers, in the presence of a lipid bilayer...The factors favoring penetration and dissociation have also been analyzed, together with membrane perturbation due to the interaction with the drug carrier complex. Our results confirm the suitability of this encapsulation strategy for PDT and rationalize the experimental results concerning its efficacy.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma, Amdray (valspodar) / Novartis, Litx (talaporfin) / Light Sciences Oncology
Preclinical, Journal: Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro. (Pubmed Central) - Oct 15, 2024
In summary, our study provided new knowledge that temoporfin, talaporfin sodium, methylene blue, and indocyanine green are not substrates of ABCG2, P-gp, or MRP1...Rose bengal is a substrate of ABCG2, P-gp, and MRP1. The results presented here indicate ABC transporter substrate status as a possible cause for cellular resistance to photodynamic therapy with rose bengal, redaporfin, and BPD.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Spectroscopic insights into BSA-mediated deaggregation of (Pubmed Central) - Sep 28, 2024
These results underscore the potential of BSA to preserve the monomeric form of m-THPC, mitigating aggregation-induced losses in singlet oxygen production. Our findings suggest that BSA-mediated delivery systems could play a crucial role in optimizing the clinical utility of hydrophobic photosensitizers like m-THPC.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma, mosnodenvir (JNJ-1802) / J&J, EYU688 / Novartis
Preclinical, Review, Journal: Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. (Pubmed Central) - Sep 14, 2024
Compound 71, a competitive NS2B-NS3 inhibitor, emerges as a leading preclinical candidate due to its high cellular antiviral efficacy, minimal cytotoxicity, and favorable in vitro pharmacokinetic parameters. Challenges remain in developing competitive NS2B-NS3 inhibitors, including appropriate biochemical inhibition assays as well as the selectivity and conformational flexibility of the protease, complicating effective antiviral treatment design.
- |||||||||| Photofrin (porfimer sodium) / Advanz Pharma, Foscan (temoporfin) / ABVC BioPharma
Journal: Computational modelling of the therapeutic outputs of photodynamic therapy on spheroid-on-chip models. (Pubmed Central) - Aug 19, 2024
The composition of PS is critical, as ALA-PpIX induces earlier cell death but accelerates oxygen consumption, especially in the outer layers, depriving the inner layers of oxygen necessary for PDT, which in turn disrupts and prolongs the exposure time compared to mTHPC and Photofrin. Despite the fluence rate directly influencing the singlet oxygen generation rate, increasing the fluence rate by 189
- |||||||||| RGC-1502 / ABVC BioPharma, Rgene Corp
Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer (clinicaltrials.gov) - Aug 9, 2024
P2, N=40, Not yet recruiting,
have greater chemical stability, tissue penetration, and may be more efficacious on recurrent OSCC. Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
- |||||||||| ABV-1504 / ABVC BioPharma, BLI-1008 / ABVC BioPharma
Trial completion, Trial completion date, Trial primary completion date: PDC-1421 Treatment in Adult Patients With ADHD (clinicaltrials.gov) - Aug 9, 2024
P2, N=70, Completed,
Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026 Suspended --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
- |||||||||| Qelbree (viloxazine) / Supernus Pharma, Knight Therap, BLI-1008 / ABVC BioPharma
Journal: The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. (Pubmed Central) - Jun 20, 2024
Adrenergic neurotransmitter reuptake inhibitors fit the diverse needs of children and adolescents with ADHD with 1) poor tolerability to stimulants (e.g. due to growth suppression, insomnia, rebound irritability, co-morbid depression, anxiety and tic disorders, substance abuse or diversion concerns), 2) cardiac risks, and/or 3) need for extended duration of action. Their differences in receptor affinities and modulating effects support the unique benefits of individual agents.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma, Litx (talaporfin) / Light Sciences Oncology, Visudyne (verteporfin) / Novartis
Journal: Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope. (Pubmed Central) - Jun 19, 2024
Our results suggest that viral envelope affinity, with penetration and destabilization of the lipid bilayer, seems critical to mediate PDs antiviral activity. Altogether, these findings open new avenues for the off-label application of temoporfin and verteporfin in the systemic treatment of COVID-19.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Amphiphilic Chlorin-?-cyclodextrin Conjugates in Photo-Triggered Drug Delivery: The Role of Aggregation. (Pubmed Central) - Jun 17, 2024
The chlorin-?-cyclodextrin conjugates displayed less-lasting effects with time, compared to the corresponding porphyrin-?-cyclodextrin conjugates, possibly due to lower tamoxifen loading of their aggregates and/or their less effective lodging in the cell compartments' membranes. The results suggest that further to favorable photophysical properties, other parameters are important for the in vitro effectiveness of the photodynamic systems.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal, Combination therapy: Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer. (Pubmed Central) - Jun 5, 2024
Here, we designed novel biomimetic nanoparticles based on homologous tumor cell membranes and poly(lactic-co-glycolic acid) (PLGA)/poly(beta-aminoester) (PBAE), denoted MDM@TPP, which efficiently coloaded the cytolytic peptide Mel and the photosensitizer mTHPC...Moreover, Mel combined with photodynamic therapy (PDT) can synergistically kill tumor cells and induce significant immunogenic cell death, thereby stimulating the maturation of dendritic cells (DCs). In 4T1 tumor-bearing mice, MDM@TPP nanoparticles effectively inhibited the growth and metastasis of primary tumors and finally prevented tumor recurrence by improving the immune response.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle. (Pubmed Central) - Apr 5, 2024
Photodynamic therapy (PDT) at 24 h in vivo showed a 4-fold reduction in tumour volume compared to control mouse xenografts (p < 0.0001). This study demonstrates the efficacy of targeted fluorescence imaging and PDT using Foslip nanoparticles conjugated to anti-CEA Affimer nanoparticles in in vitro and in vivo colorectal cancer models.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Preclinical, Journal: Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy. (Pubmed Central) - Mar 4, 2024
bPDT required ip bolus of mTHPC (photosensitiser) and delivery of the d-luciferin substrate over 7 days via an implanted osmotic pump...(P<0.001) This study reports bPDT suppression of tumour growth from luciferase transfected astrocytoma cells with all components of treatment given systemically, as required for effective management of recurrent astrocytomas in unknown sites. However, research on systemic bPDT is needed to establish whether effects on non-transfected tumours can be achieved without any unacceptable effects on normal tissues.
- |||||||||| ABV-1504 / ABVC BioPharma, BLI-1008 / ABVC BioPharma
Trial suspension: PDC-1421 Treatment in Adult Patients With ADHD (clinicaltrials.gov) - Mar 2, 2024
P2, N=99, Suspended,
However, research on systemic bPDT is needed to establish whether effects on non-transfected tumours can be achieved without any unacceptable effects on normal tissues. Recruiting --> Suspended
- |||||||||| Visudyne (verteporfin) / Novartis
Journal: Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. (Pubmed Central) - Jan 24, 2024
Temoporfin, another photodynamic drug, did not show similar activities...Notably, the activity of VP to induce lipid peroxidation was neutralized by ferroptosis inhibitors ferrostatin-1 or liproxstatin-1...These results indicate that VP can induce lipid peroxidation and ferroptosis in the absence of light activation. Our findings reveal a novel mechanism by which VP inhibits tumor growth and provide insights into development of new therapeutic strategies for the treatment of pancreatic cancer.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Antitumor Immunity Mediated by Photodynamic Therapy Using Injectable Chitosan Hydrogels for Intratumoral and Sustained Drug Delivery. (Pubmed Central) - Jan 9, 2024
For this, Temoporfin (m-THPC), which is one of the most potent clinical photosensitizers, was chemically modified to introduce functional groups that act as cross-linkers in the formation of chitosan-based hydrogels...Additionally, the failure of PDT to treat immunocompromised mice bearing tumors reinforces the relevance of the host immune system. Finally, our strategy promotes anticancer immune responses that lead to the abscopal protection against distant metastases.
- |||||||||| RGC-1501 / ABVC BioPharma, Rgene Corp
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=32, Not yet recruiting,
Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Apr 2025 Trial completion date: Jun 2025 --> Jun 2026 | Initiation date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jan 2026
- |||||||||| RGC-1502 / ABVC BioPharma, Rgene Corp
Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer (clinicaltrials.gov) - Nov 18, 2023
P2, N=40, Not yet recruiting,
Trial completion date: Jun 2025 --> Jun 2026 | Initiation date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jan 2026 Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
- |||||||||| ABV-1601 / ABVC BioPharma, ABV-1504 / ABVC BioPharma
Trial completion date, Trial primary completion date: A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=12, Not yet recruiting,
Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Apr 2026 Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Mar 2024 --> Feb 2025
- |||||||||| Photofrin (porfimer sodium) / Advanz Pharma, Foscan (temoporfin) / ABVC BioPharma, Visudyne (verteporfin) / Novartis
Review, Journal: Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials. (Pubmed Central) - Sep 28, 2023
In lung cancer, porfimer sodium, chlorin e6, and verteporfin have shown promising results in preclinical studies and clinical trials...PDT with temoporfin, redaporfin, photochlor, and IR700 shows potential in early stage larynx cancer and recurrent head and neck carcinoma...In conclusion, PDT continues to evolve as a promising cancer treatment strategy, with ongoing research spanning from fundamental investigations to clinical trials, exploring various photosensitizers and treatment combinations. This review sheds light on the recent advancements in PDT for cancer therapy and highlights its potential for personalized and targeted treatments.
- |||||||||| Photofrin (porfimer sodium) / Advanz Pharma, Foscan (temoporfin) / ABVC BioPharma, Litx (talaporfin) / Light Sciences Oncology
Review, Journal: Photosensitizers for Photodynamic Therapy of Brain Cancers-A Review. (Pubmed Central) - Sep 28, 2023
An overview of all three generations of photosensitizers is presented. Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Journal: Novel Foscan (Pubmed Central) - Sep 22, 2023
Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method. These chlorins have photochemical properties similar to Foscan
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers (clinicaltrials.gov) - Aug 22, 2023
P2, N=10, Completed,
Both biomaterials, especially BioM1 showed good osseointegration and bone formation characteristics and can be recommended for further examination in periodontal regeneration studies. Recruiting --> Completed | N=20 --> 10 | Trial completion date: Aug 2024 --> Aug 2023 | Trial primary completion date: Aug 2023 --> Apr 2023
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Foscan (temoporfin) / ABVC BioPharma, Rydapt (midostaurin) / Novartis
Journal: Polypharmacology guided drug repositioning approach for SARS-CoV2. (Pubmed Central) - Aug 13, 2023
As drug resistance is one of the major challenges in antiviral drug discovery, polypharmacology and network pharmacology approaches were employed in the study to identify drugs interacting with multiple targets and drugs such as dihydroergotamine, ergotamine, bisdequalinium chloride, midostaurin, temoporfin, tirilazad, and venetoclax were identified among the multi-targeting drugs. Further, a pathway analysis of the genes related to the multi-targeting drugs was carried which provides insight into the mechanism of drugs and identifying targetable genes and biological pathways involved in SARS-CoV2.
- |||||||||| Foscan (temoporfin) / ABVC BioPharma
Preclinical, Review, Journal: Photodynamic Therapy of Breast Cancer in Animal Models and Their Potential Use in Clinical Trials-Role of the Photosensitizers: A Review. (Pubmed Central) - Aug 1, 2023
Herein, we discuss the use of five photosensitizers in BC models such as chlorin e6 (Ce6), methylene blue, indocyanine green, 5-aminolevulinic acid, and meta-tetra(hydroxyphenyl)chlorin...The PDT search results in animal experiments and its effect on a living organism indicate the possibility of its application in clinical trials on women with local and disseminated BC. The availability and accessibility of small and large BC animal models enable the progress and trial of cancer drugs for innovative technologies and new diagnostics and treatments.
|
